The global biobanks market size was estimated at USD 65.9 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.2% from 2021 to 2028. High investments for R&D of advanced therapies such as regenerative medicine, personalized medicine, and cancer genomic studies are driving the space. Moreover, the onset of COVID-19 has put biobanks at the forefront of pandemic control measures, resulting in the organic revenue growth of the market.
The increasing popularity of precision/personalized medicine and genetic testing has been a key driver of the market. Biobanks have been playing a significant role in biomedical research. Over the past few decades, there have been several advances in platforms and tools used in genetic studies. This has led to an increase in demand for biospecimens from clinical labs to develop assays for genetic testing.
Collaborations between private and public institutions in biobanking have played a crucial role in market progression. Digitalization, precision medicine, and virtualization are rapidly changing the biobanking industry by the development of novel methods and concepts of synergies initiated by public and private organizations. Companies across all fields are partnering with biobanks which accelerates the market revenue.
For instance, Illumina partnered with four institutions - the University of Colorado at Denver, Vanderbilt University, Montreal Heart Institute University, and Partners HealthCare - to genotype their bio-samples for R&D activities. Moreover, despite the supply chain hindrance by a global pandemic, the market witnessed lucrative growth in 2020. This is because biobanking has emerged as a key focal point for public health agencies and healthcare providers engaged in curbing the COVID-19 pandemic.
An exponential increase in the number of global cases has rendered the significance of biobanks in containing the spread of the virus. High-quality COVID-19 specimens are required and helpful for both research and diagnostic purposes, and biobanks are considered as vital repositories for these samples. Thus, biobanks are gaining ground to support clinical research and drug discovery processes to combat this global disaster.
The biobanking equipment segment dominated the market for biobanks and accounted for the largest revenue share of 78.0% in 2020, owing to a rapid increase in the number of new biobanks and the high cost of initial equipment installation. A wide range of equipment is offered to cater to different biobanking processes such as sample preparation, collection, processing, storage, and shipment. The equipment includes cell separators, freezers, thawing equipment, barcode readers, and alarm and monitoring systems.
The Laboratory Information Management Systems (LIMS) segment is anticipated to emerge as a lucrative source of revenue during the forecast period. This is because LIMS plays an important role in COVID-19 biobanking, testing, and research. In April 2020, LabVantage Solutions, Inc. developed a new COVID-19 LIMS solution. Besides, CloudLIMS is offering its cloud LIMS free of charge to biobanks, research facilities, and laboratories undertaking COVID-19 research or testing across the globe.
The biobanking and repository services segment dominated the market for biobanks and accounted for the largest revenue share of 36.0% in 2020. This is owing to the higher market penetration of these services and the increased need for the preservation of biosamples for developing precision medicine and disease-specific research. Expansion of biobanking services from academic research to include clinical enterprises and government initiatives, as well as highly networked and open-ended ventures, has fomented the segment.
The lab processing segment is expected to witness growth in the near future due to the increasing demand for clinical trials and research-related workflows around COVID-19. Many research institutes and companies are engaged in the development of vaccines and research studies for the novel coronavirus. This is expected to increase the demand for lab processing services, such as DNA extraction, plasma/serum isolation, sample retrieval, and sample plating.
The human tissues segment dominated the market for biobanks and accounted for the largest revenue share of 38.0% in 2020. This is owing to a large number of biobanks with facilities to store tissues, easy availability of tissue samples, and availability of advanced technology for storage and retrieval of banked tissues. Growing investment in disease-specific R&D is anticipated to foster the demand for diseased tissue samples such as lymphoma, myeloma, ovarian leukemia, brain, prostate, colorectal carcinoma breast, and lung tissues for oncology studies.
In the effort to advance the research on COVID-19 and improve its diagnosis and treatment, the human tissue segment is expected to witness high demand in the near future. Technological advancements such as the use of 3D-printing for tissue sample/3D-printed mini-organs creation in COVID-19 testing are expected to boost the segment growth.
The number of established stem cell biobanks has been increasing rapidly worldwide. Promising applications of stem cells in regenerative medicine, cell therapy, developmental biology, toxicology, and drug development can be attributed to the rapid increase in the number of stem cell banks, resulting in the lucrative revenue growth of this segment.
The physical/real biobanks segment dominated the market for biobanks and accounted for the largest revenue share of 82.0% in 2020. These biobanks have a well-established network, thereby hold a high revenue share. Rapid progress in the fields of bioinformatics analysis and precision medicine can be attributed to this change in the operating strategy of the biobanks. A large collection of tissue samples from pathological labs, clinical trials, and research projects over the years contributes to the largest share of tissue banks in 2020.
However, in recent years, virtual biobanks have emerged to address problems related to the accessibility of biospecimens. Tissue Solutions (Scotland) and Human Focused Testing (Little port) are examples of organizations whose core operating activity involves procurement and distribution of samples as per requirement. The potential to fulfill the need for biospecimens and the ability to trace and obtain rare samples improves with virtual biobanking. Also, easy accessibility associated with virtual biobanks contributes to the lucrative growth of the segment.
In 2020, the drug discovery and clinical research application segment dominated the biobanks market with a revenue share of 38.0%. This can be attributed to the ever-increasing demand for bio-sample for new drug testing in clinical studies. Furthermore, the exponential increase in the number of COVID-19 cases across the globe has resulted in an increasing need for vaccine development. Various studies are being conducted to accelerate research in this field.
For instance, Mayo Clinic has initiated an observational study for prospectively collecting research biospecimens and clinical data from COVID-19 patients, to enable high-quality research, thereby driving the segment growth. On the other hand, the clinical diagnostics segment is anticipated to witness the fastest growth throughout the forecast period. Comparison of biospecimens obtained from healthy and diseased individuals advances the clinical diagnosis process, especially for cancer. It helps investigate the treatment response of the patient and identify a new tumor in a patient with a history of cancer.
North America accounted for the maximum revenue share of 34% in the 2020 global market owing to the continuous investment in the collection, establishment, and processing of large-scale datasets. For instance, in March 2019, the UK Biobank generated exome sequence data from 50,000 people with an objective to advance disease management including prevention, diagnosis, and treatment. That project aims to collect data of about 500,000 people and follow their health.
In March 2020, the Columbia University and New York-Presbyterian Hospital established a COVID-19 biobank for researchers to accelerate their studies. Furthermore, in April 2020, Biogen, Inc., in collaboration with Partners HealthCare and Broad Institute of MIT, announced the association for building a COVID-19 biobank. In April 2020, Québec COVID-19 Biobank began operating in Canada. This biobank was launched by Genome Québec and the Fonds de recherche du Québec. Such developments are expected to drive the revenue flow in this region.
With the increasing availability of biospecimens, the market participants are expanding their offerings to keep pace with the rising demand for bio-storage solutions. For instance, in February 2020, Hamilton Storage launched new sample storage tubes along with RackWare racks at SLAS 2020 International Conference and Exhibition. Furthermore, the market players are engaged in strategic alliances with research communities and healthcare organizations to effectively serve the biobanking demand for the storage and processing of biosamples. Some of the prominent players in the biobanks market include:
Thermo Fisher Scientific, Inc.
Tecan Trading AG.
Becton, Dickinson and Company (BD)
Charles River Laboratories
STEMCELL Technologies Inc.
Precision Cellular Storage Ltd. (Virgin Health Bank)
Market size value in 2021
USD 73.3 billion
Revenue forecast in 2028
USD 106.9 billion
CAGR of 6.2% from 2021 to 2028
Base year for estimation
2017 - 2019
2021 - 2028
Revenue in USD Million and CAGR from 2021 to 2028
Revenue forecast, company share, competitive landscape, growth factors, and trends
Product, service, biospecimen type, biobanks type, application, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; U.K.; France; Spain; Italy; Japan; China; India; Australia; Singapore; Brazil; South Africa
Key companies profiled
Thermo Fisher Scientific, Inc.; Merck KGaA; QIAGEN; Hamilton Company; Avantor; Tecan Trading AG.; Danaher Corporation; Becton, Dickinson and Company (BD); BioCision; Taylor-Wharton; Charles River Laboratories; Lonza; STEMCELL Technologies Inc.; Biovault Family; PromoCell GmbH; Precision Cellular Storage Ltd. (Virgin Health Bank)
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global biobanks market report on the basis of product, service, biospecimen type, biobanks type, application, and region:
Product Outlook (Revenue, USD Million, 2017 - 2028)
Temperature Control Systems
Freezers & Refrigerators
Cryogenic Storage Systems
Incubators & Centrifuges
Alarms & Monitoring Systems
Accessories & Other Equipment
Laboratory Information Management Systems
Service Outlook (Revenue, USD Million, 2017 - 2028)
Biobanking & Repository
Cold Chain Logistics
Biospecimen Type Outlook (Revenue, USD Million, 2017 - 2028)
Adult Stem Cells
Embryonic Stem Cells
Other Stem Cells
Biobank Type Outlook (Revenue, USD Million, 2017 - 2028)
Population Based Biobanks
Disease Based Biobanks
Application Outlook (Revenue, USD Million, 2017 - 2028)
Drug Discovery & Clinical Research
Regional Outlook (Revenue, USD Million, 2017 - 2028)
Middle East & Africa
b. The global biobanks market size was estimated at USD 66 billion in 2020 and is expected to reach USD 73.3 billion in 2021.
b. The global biobanks market is expected to grow at a compound annual growth rate of 6.2% from 2021 to 2028 to reach USD 106.9 billion by 2028.
b. Equipment dominated the biobanks market with a share of 78% in 2020. This is attributable to the presence of a wide range of equipment are available for biobanking processes such as sample collection, storage, analysis, preparation, and transport.
b. Some key players operating in the biobanks market include Thermo Fisher Scientific, Inc.; Merck KGaA; Qiagen; Hamilton Company; VWR International, LLC; Tecan Trading AG.; Danaher; BioCision; Charles River; Lonza; Biovault; and STEMCELL Technologies Inc.
b. Key factors that are driving the market growth are the increasing popularity of fertility preservation services, investment in facility expansion for biobanking, and growing collaborations between biobanks and end-users.
b. North America accounted for the maximum revenue share of 34% in the 2020 global biobanks market owing to the continuous investment in the collection, establishment, and processing of large-scale datasets.
b. Recently, in February 2020, Hamilton Storage launched new sample storage tubes in the biobanks market along with RackWare racks at SLAS 2020 International Conference and Exhibition.
b. The human tissues segment dominated the biobanks market and accounted for the largest revenue share of 38.0% in 2020, due to a large number of biobanks with facilities to store tissues, easy availability of tissue samples, and availability of advanced technology for storage and retrieval of banked tissues.
b. In 2020, the drug discovery and clinical research application segment dominated the biobanks market with a revenue share of 38.0% and it can be attributed to the ever-increasing demand for bio-sample for new drug testing in clinical studies.
b. The biobanking and repository services segment dominated the biobanks market and accounted for the largest revenue share of 36.0% in 2020, owing to the higher market penetration of these services and the increased need for the preservation of biosamples for developing precision medicine and disease-specific research.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.